NCT00104507已完成2 期
A 4-Week, Dose-ranging, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of APD356 in Obese Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 400
- 试验地点
- 2
- 主要终点
- Change in body weight
研究概览
简要总结
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.
详细描述
This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 28 days, to uncomplicated obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Change in body weight
次要结局
- Safety
- Changes in waist circumference, hip circumference and waist/hip ratio
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of APD356 in the Treatment of ObesityObesityNCT00116740Eisai Inc.400
已完成
1 期
Effect of ATI-7505 on Gastrointestinal Transit in Healthy VolunteersHealthyNCT01094821Mayo Clinic48
终止
1 期
A Safety and Tolerability Study of AG-519 in Healthy SubjectsAnemiaNCT02630927Agios Pharmaceuticals, Inc.108
已完成
2 期
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)HypertensionDiabetes Mellitus, Type 2NCT01096667Merck Sharp & Dohme LLC194
已完成
2 期
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)Diabetes Mellitus, Type 2NCT01059825Merck Sharp & Dohme LLC375